Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H2 2018
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Pipeline Review, H2 2018
SUMMARY
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo%li%or hetero-dimers that interact with specific DNA sequences to activate transcription.
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 2, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Oncology, Metabolic Disorders, Women's Health, Male Health and Immunology which include indications Breast Cancer, Endometriosis, Multiple Sclerosis, Osteoporosis, Alzheimer's Disease, Hormone Sensitive Breast Cancer, Neuropathic Pain (Neuralgia), Prostate Cancer, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Cognitive Impairment Associated With Schizophrenia (CIAS), Colon Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Fallopian Tube Cancer, Inflammation, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic’s Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
The latest report Estrogen Receptor Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo%li%or hetero-dimers that interact with specific DNA sequences to activate transcription.
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) pipeline Target constitutes close to 21 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 3, 2, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Oncology, Metabolic Disorders, Women's Health, Male Health and Immunology which include indications Breast Cancer, Endometriosis, Multiple Sclerosis, Osteoporosis, Alzheimer's Disease, Hormone Sensitive Breast Cancer, Neuropathic Pain (Neuralgia), Prostate Cancer, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Carcinomas, Cognitive Impairment Associated With Schizophrenia (CIAS), Colon Cancer, Demyelinating Diseases, Depression, Ductal Carcinoma In Situ, Fallopian Tube Cancer, Inflammation, Male Hypogonadism, Malignant Pleural Mesothelioma, Neuromyelitis Optica (Devic’s Syndrome), Obesity, Ovarian Cancer, Peritoneal Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).
The latest report Estrogen Receptor Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
- The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development
Acadia Pharmaceuticals Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Eli Lilly and Co
Endece LLC
EndoCeutics Inc
Huons Global Co Ltd
Karo Pharma AB
Kissei Pharmaceutical Co Ltd
MEI Pharma Inc
Oasmia Pharmaceutical AB
ViroMed Co Ltd
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + GnRH Agonist + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erteberel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-3944 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-9520 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones
Featured News & Press Releases
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Dec 11, 2017: AstraZeneca’s Faslodex Rejects for Use within NHS Scotland
Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer
Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer
Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study
Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
Feb 13, 2017: ENDECE Opens San Francisco Office
Jan 09, 2017: Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development
Acadia Pharmaceuticals Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Eli Lilly and Co
Endece LLC
EndoCeutics Inc
Huons Global Co Ltd
Karo Pharma AB
Kissei Pharmaceutical Co Ltd
MEI Pharma Inc
Oasmia Pharmaceutical AB
ViroMed Co Ltd
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles
(bazedoxifene acetate + cholecalciferol) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + GnRH Agonist + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene + prasterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acolbifene hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dehydrodiconiferyl alcohol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize ER-Beta for Multiple Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
erteberel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosfestrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-3944 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KB-9520 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Loseasonique - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1308 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NDC-1352 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Estrogen Beta Receptor for Inflammatory Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-16234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products
Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones
Featured News & Press Releases
Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
Dec 11, 2017: AstraZeneca’s Faslodex Rejects for Use within NHS Scotland
Dec 07, 2017: Eagle Pharmaceuticals Commences Pivotal Study for Fulvestrant
Nov 15, 2017: Faslodex receives US FDA approval for the treatment of advanced breast cancer in combination with abemaciclib
Nov 14, 2017: Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer in Combination with Palbociclib
Oct 13, 2017: Faslodex (Fulvestrant) Receives Positive CHMP Opinion For The Treatment Of Hormone Receptor-Positive Advanced Breast Cancer In Combination With Palbociclib
Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective
Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer
Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer
Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study
Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer
May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
Feb 13, 2017: ENDECE Opens San Francisco Office
Jan 09, 2017: Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acadia Pharmaceuticals Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Atossa Genetics Inc, H2 2018
Pipeline by Avivia BV, H2 2018
Pipeline by Eagle Pharmaceuticals Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Endece LLC, H2 2018
Pipeline by EndoCeutics Inc, H2 2018
Pipeline by Huons Global Co Ltd, H2 2018
Pipeline by Karo Pharma AB, H2 2018
Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Pipeline by MEI Pharma Inc, H2 2018
Pipeline by Oasmia Pharmaceutical AB, H2 2018
Pipeline by ViroMed Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Acadia Pharmaceuticals Inc, H2 2018
Pipeline by AstraZeneca Plc, H2 2018
Pipeline by Atossa Genetics Inc, H2 2018
Pipeline by Avivia BV, H2 2018
Pipeline by Eagle Pharmaceuticals Inc, H2 2018
Pipeline by Eli Lilly and Co, H2 2018
Pipeline by Endece LLC, H2 2018
Pipeline by EndoCeutics Inc, H2 2018
Pipeline by Huons Global Co Ltd, H2 2018
Pipeline by Karo Pharma AB, H2 2018
Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018
Pipeline by MEI Pharma Inc, H2 2018
Pipeline by Oasmia Pharmaceutical AB, H2 2018
Pipeline by ViroMed Co Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Acadia Pharmaceuticals Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Eli Lilly and Co
Endece LLC
EndoCeutics Inc
Huons Global Co Ltd
Karo Pharma AB
Kissei Pharmaceutical Co Ltd
MEI Pharma Inc
Oasmia Pharmaceutical AB
ViroMed Co Ltd
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Acadia Pharmaceuticals Inc
AstraZeneca Plc
Atossa Genetics Inc
Avivia BV
Eagle Pharmaceuticals Inc
Eli Lilly and Co
Endece LLC
EndoCeutics Inc
Huons Global Co Ltd
Karo Pharma AB
Kissei Pharmaceutical Co Ltd
MEI Pharma Inc
Oasmia Pharmaceutical AB
ViroMed Co Ltd
